Nyman, Emma
Liv, Per
Wester, Per
Näslund, Ulf
Grönlund, Christer
Funding for this research was provided by:
Heart Foundation in Northern Sweden
Region Västerbotten, Sweden (ALFVLL-298001, ALFVLL643391)
Hjärt-Lungfonden (20150369, 20170481)
Umea University
Article History
Received: 15 September 2022
Accepted: 17 November 2022
First Online: 21 January 2023
Declarations
:
: Founding.
: This work was supported by Region Västerbotten (Central ALF, Dnr ALFVLL-298001 and ALFVLL643391), the Swedish Research Council (Dnr 521-2013-2708, 2016 − 01891), the Heart and Lung Foundation (Dnr 20150369, 20170481), SKANDIA Risk & Health, and an unconditional donation from Carl Bennet Ltd, Sweden. VIPVIZA was also funded by the Swedish Society of Medicine, the Heart Foundation in Northern Sweden, STROKE – the national association, The Swedish Insurance Society, Visare Norr (the four Northern Regions), and the Swedish and the Västerbotten Heart and Lung Associations. The funders of the study had no role in the study design, data collection, data interpretation, or writing of the report.
: The authors have no relevant financial or non-financial interests to disclose.
: Author Contributions.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Emma Nyman, Per Liv and Christer Grönlund. The first draft of the manuscript was written by Emma Nyman and all authors commented on previous versions and approved the final manuscript.